Autologous fat grafting as a mesenchymal stem cell source and living bioscaffold in a patellar tendon tear
JJ Albano, RW Alexander - Clinical Journal of Sport Medicine, 2011 - journals.lww.com
JJ Albano, RW Alexander
Clinical Journal of Sport Medicine, 2011•journals.lww.comDISCUSSION Platelet-rich plasma is one of the most common biologic treatments used in
musculoskeletal (MSK) injuries 1, 2 and has become more familiar to the general public with
treatments of several high-profile athletes. It is increasingly recognized as an effective
treatment in various MSK injuries, including tendinosis, partial thickness tears, and interstitial
tears. The regenerative potential of pleuripotent progenitor cells (mesenchymal stem cells)
in bone marrow and adipose tissue has led to their consideration in MSK applications as …
musculoskeletal (MSK) injuries 1, 2 and has become more familiar to the general public with
treatments of several high-profile athletes. It is increasingly recognized as an effective
treatment in various MSK injuries, including tendinosis, partial thickness tears, and interstitial
tears. The regenerative potential of pleuripotent progenitor cells (mesenchymal stem cells)
in bone marrow and adipose tissue has led to their consideration in MSK applications as …
DISCUSSION
Platelet-rich plasma is one of the most common biologic treatments used in musculoskeletal (MSK) injuries 1, 2 and has become more familiar to the general public with treatments of several high-profile athletes. It is increasingly recognized as an effective treatment in various MSK injuries, including tendinosis, partial thickness tears, and interstitial tears. The regenerative potential of pleuripotent progenitor cells (mesenchymal stem cells) in bone marrow and adipose tissue has led to their consideration in MSK applications as well. In animal MSK models 3 and human aesthetic applications, 4-6 the use of these tissues has been demonstrated to be safe and efficacious.
Lippincott Williams & Wilkins